Author’s response to reviews

Title: Understanding Side Effects of Therapy for Myasthenia Gravis and their Impact on Daily Life

Authors:

Elizabeth Bacci (elizabeth.bacci@evidera.com)
Karin Coyne (karin.coyne@evidera.com)
Jiat Ling-Poon (poon_jiat_ling@lilly.com)
Linda Harris (linda.harris@alexion.com)
Audra Boscoe (audra.boscoe@gmail.com)

Version: 2 Date: 05 Dec 2019

Author’s response to reviews:

December 5, 2019

Re: Manuscript ID NURL-D-19-00085R1

To Whom It May Concern:

We have revised the manuscript, “Understanding Side Effects of Therapy for Myasthenia Gravis and their Impact on Daily Life,” based on the feedback the reviewers and editorial team have provided. We are grateful for the reviewers’ comments and provisional acceptance of the manuscript.

Below are our responses to each of the comments.

Reviewer(s)’ Comments to Author

Reviewer #1

The authors explained that "Refractory" defined as being unresponsive to treatment. I'm not still sure about the definition of "unresponsive to treatment". Do you mean MGFA postintervention status "Unchanged” or less status? Please clarify.
Thank you for this comment. We agree with your terminology and have revised accordingly in the Statistical Analysis section, paragraph 2, as well as in the footnote of Table 1.

Reviewer #2

- I think that the manuscript has been adequately revised.
- Thank you for your final review.

Reviewer #3

- The authors addressed the questions and the manuscript can be published.
- Thank you for your final review.

Reviewer #4

- I think this work by the authors is quite relevant and important in the field of Myasthenia. Some of the side effect burden in this patient group was likely underestimated for many years.

Refractory or non refractory status has many different definitions and I am glad authors have defined on how this was used in this study. Can authors verify that antibody status were not verified in this study? and IVIG use was only patient reported and there was no further external validation. Antibody status is relevant because symptoms burden may vary between AChR and MuSK antibodies

- Thank you for your comments. The reviewer is correct; antibody status was not verified as this study was based on participant self-report. IVIG was also collected via self-report only. The manuscript was revised to make this clear in the Statistical Analysis section, paragraph 2

Editorial Policies

Please read the following information and revise your manuscript as necessary. If your manuscript does not adhere to our editorial requirements, this may cause a delay while this is addressed. Failure to adhere to our policies may result in rejection of your manuscript.

In accordance with BioMed Central editorial policies and formatting guidelines, all manuscript submissions to BMC Neurology must contain a Declarations section which includes the mandatory sub-sections listed below. Please refer to the journal's Submission Guidelines web
page for information regarding the criteria for each sub-section (https://bmcneurol.biomedcentral.com/).

Where a mandatory Declarations section is not relevant to your study design or article type, please write "Not applicable" in these sections.

For the 'Availability of data and materials' section, please provide information about where the data supporting your findings can be found. We encourage authors to deposit their datasets in publicly available repositories (where available and appropriate), or to be presented within the manuscript and/or additional supporting files. Please note that identifying/confidential patient data should not be shared. Authors who do not wish to share their data must confirm this under this sub-heading and also provide their reasons. For further guidance on how to format this section, please refer to BioMed Central's editorial policies page (see links below).

Declarations

- Ethics approval and consent to participate
- Consent for publication
- Availability of data and materials
- Competing interests
- Funding
- Authors' Contributions
- Acknowledgements

- All declarations are included, and the Availability of Data and Materials section has been updated.